ImmunoVec is pioneering a new class of programmable DNA medicines that bring precision and durability to in vivo cell therapy.

By combining programmable DNA with cell type-specific transcriptional control and novel targeted delivery technologies, the company’s proprietary platform enables precise engineering of specific cell types directly within the body, unlocking a new generation of therapies for autoimmune diseases, cancers, and genetic disorders.